The flaviviral envelope proteins, E protein and precursor membrane protein, are mainly associated with the endoplasmic reticulum (ER) through two transmembrane (TM) domains that are exposed to the luminal face of this compartment. Their retention is associated with the viral assembly process. ER-retrieval motifs were mapped at the carboxy terminus of these envelope proteins. A recombinant yellow fever (YF) 17D virus expressing the reporter green fluorescent protein (GFP) with the stem-anchor (SA) region of E protein fused to its carboxy terminus was subjected to distinct genetic mutations in the SA sequence to investigate their effect on ER retention. Initially, we introduced progressive deletions of the stem elements (H1, CS and H2). In a second set of mutants, the effect of a length increase for the first TM anchor region was evaluated either by replacing it with the longer TM of human LAMP-1 or by the insertion of the VALLLVA sequence into its carboxy terminus. We did not detect any effect on the GFP localisation in the cell, which remained associated with the ER. Further studies should be undertaken to elucidate the causes of the ER retention of recombinant proteins expressed at the intergenic E/NS1 region of the YF 17D virus polyprotein.

Download full-text PDF

Source
http://dx.doi.org/10.1590/s0074-02762012000200017DOI Listing

Publication Analysis

Top Keywords

17d virus
12
carboxy terminus
12
retention recombinant
8
yellow fever
8
fever 17d
8
endoplasmic reticulum
8
envelope proteins
8
protein
5
retention
4
recombinant gfp
4

Similar Publications

: Yellow fever virus (YFV) (, ) is the etiologic agent of yellow fever (YF), a vector-borne disease with significant morbidity and mortality across the tropics and neotropics, despite having a highly efficacious and safe vaccine (17D). Vaccination provides lifelong protection from YF disease mediated by humoral immunity. There are several versions of the original 17D vaccine: 17D-204 (marketed in the USA as YF-VAX, in France as Stamaril, and in China as Tiantan-V), 17D-213 (Russian Federation), and 17DD (by FIOCRUZ in Brazil).

View Article and Find Full Text PDF

Novel α-mangostin derivatives as promising antiviral agents: Isolation, synthesis, and evaluation against chikungunya virus.

Eur J Med Chem

December 2024

Department of Natural Products and Medicinal Chemistry, CSIR-IICT Hyderabad, India; Academy of Scientific and Innovative Research (AcSIR), Ghaziabad, 201002, India. Electronic address:

Investigations into fruit and vegetable processing residues (FVPRs) offer huge opportunities to discover novel therapeutics against many diseases. In this study, detailed investigation of Garcinia mangostana fruit peel extract led to the isolation and identification of ten known compounds (1-10). Further, a new series of α-mangostin derived sulphonyl piperzines, aryl alkynes and 1,2,3-triazole derivatives were synthesized using Huisgen 1,3-dipolar cyclo-addition reaction ("click" chemistry).

View Article and Find Full Text PDF

In the 2018 yellow fever (YF) outbreak in Brazil, we generated new transcriptomic data and combined it with clinical and immunological data to decode the pathogenesis of YF. Analyzing 79 patients, we found distinct gene expression patterns between acute YF, other viral infections, and the milder YF-17D vaccine infection. We identified a critical role for low-density, immature neutrophils in severe outcomes, marked by the downregulation of genes essential for neutrophil migration and maturation, such as PADI4, CSF3R, and ICAM1, in deceased patients.

View Article and Find Full Text PDF

Long-term immunity after vaccination against yellow fever in Korean travelers.

Jpn J Infect Dis

November 2024

Division of Infectious Diseases, Department of Internal Medicine, National Medical Center, Korea.

While a live-attenuated Yellow fever (YF) vaccine is known to elicit durable immunity, antibody titers may wane after vaccination. This study evaluated the long-term immunity after vaccination against YF among individuals who reside in Korea and received vaccination with YF virus-17D prior to international travel. Serum was collected between December 2018 and December 2019 at the National Medical Center, Republic of Korea from YF vaccine recipients who were vaccinated more than five years prior to sample collection.

View Article and Find Full Text PDF

Breakthroughs and insights: A comprehensive review of yellow fever vaccine breakthrough infection across 8 decades.

Vaccine

January 2025

Department of Molecular Microbiology and Immunology, 3181 SW Sam Jackson Park Road, Oregon Health and Science University, Portland, Oregon 97239, USA; Associate Professor, Department of Molecular Microbiology and Immunology, 3181 SW Sam Jackson Park Road, Oregon Health and Science University, Portland, Oregon 97239, USA; Department of Medicine, 3181 SW Sam Jackson Park Road, Oregon Health and Science University, Portland, Oregon 97239, USA; Program in Epidemiology, OHSU-PSU School of Public Health, 3181 SW Sam Jackson Park Road, Oregon Health and Science University, Portland, Oregon 97239, USA. Electronic address:

The yellow fever vaccine 17D is one of the most successful live-attenuated vaccines ever developed, controlling mosquito-borne yellow fever virus and yellow fever disease worldwide. Introduced in 1937, 17D never underwent rigorous phase III clinical trials to evaluate safety or efficacy, and while protection in the field was quickly established, no prospective evaluation of vaccine efficacy has ever been conducted. One important measure of vaccine efficacy is breakthrough infection resulting from vaccine failure.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!